Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos

This article was originally published in The Pink Sheet Daily

Executive Summary

Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.

Advertisement

Related Content

FDA Is Raising The Bar On Hepatitis C Approvals
J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel